About DiscGenics
DiscGenics is a Healthcare company based in Salt Lake City (United States) founded in 2008. Tissue engineering company utilizing a proprietary stem technology to treat degenerative disc disease. DiscGenics has raised $65.84 million across 3 funding rounds from investors including CareNet, Mitsubishi UFJ Capital and Medical Incubator Japan. The company has 45 employees. Its focus areas include Life Sciences, Cell Therapy, Stem Cells and Progenitor Cells. Its legal entity is DISCGENICS, INC. Its competitors include ViaCyte, Capricor Therapeutics and Neurona Therapeutics; 2 of its 3 listed competitors have raised funding.
Company details
DiscGenics was established in 2008 in Salt Lake City, United States, within the spinal therapeutics sector. A tissue engineering approach is employed, leveraging proprietary adult human disc stem cells to address degenerative disc disease. Two products are under development: Injectable Discogenic Cell Therapy (IDCT), an off-the-shelf allogeneic treatment for moderately degenerated discs delivered via non-surgical percutaneous injection, and Surgical Discogenic Cell Therapy (SDCT), a minimally invasive implant for herniated discs.
- Headquarters Salt Lake City, United States
- Employees 45
- SectorsHealthcare
- Website discgenics.com
- Social LinkedIn X Facebook
- Legal Name Discgenics, Inc.
- Total Equity Funding$65.84M (USD)
in 3 rounds
- Latest Funding Round$50M (USD), Series C
Aug 2020
- InvestorsCareNet
& 2 more
- Employee Count45
Funding Insights of DiscGenics
DiscGenics has successfully raised a total of $65.84M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $50 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $65.84M
- Total Rounds 3
- Last Round Series C — $50M
- First Round $1.84M
(Oct 2011)
- Investors Count 3
All 3 funding rounds of DiscGenics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2020 | $50M | Series C | – | – | |
| Sep 2017 | $14M | Series B | – | – | |
| Oct 2011 | $1.84M | Seed | – | – | – |
3 investors in total: 3 institutional.
Investors in DiscGenics
DiscGenics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include CareNet, Mitsubishi UFJ Capital and Medical Incubator Japan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital is invested in AI, energy, and various sectors. | mucap.co.jp | Tokyo, Japan | ||
Investment in innovative healthcare startups is facilitated by this company. | medicalincubatorjapan.com | Japan | ||
Medical sales support and education services for pharmaceuticals are provided. | 1996 | carenet.co.jp | Chiyoda City, Japan |
Investor details for DiscGenics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of DiscGenics
9 people are tracked at DiscGenics (3 in leadership, 3 in board & advisors, 3 in team); the tracked headcount is 45.
| Name | Role | Group |
|---|---|---|
Bob Wynalek | Chief Operating & Commercialization Officer, Director | Leadership |
Flagg Flanagan | Chief Executive Officer & Chairman of the Board | Leadership |
Nancy Rose | Human Resources Director | Leadership |
Colin Lee Novick | Director | Board & advisors |
Najeeb Thomas, M.D. | Director | Board & advisors |
Najeeb Thomas | Director | Board & advisors |
Megan T. | Senior Quality Assurance Analyst | Team |
Travis Lindstrom | Facility Manager | Team |
Nicole Bowen | Quality Manager | Team |
Complete people profiles for DiscGenics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of DiscGenics
3 dated milestones of DiscGenics across 12 years, from founding to its latest funding, stage changes and deals.
- Founded DiscGenics is founded.
- Funding First funding round of $1.8M.
- Funding Latest funding round, Series C, of $50.0M.
Competitors of DiscGenics
DiscGenics has 3 listed competitors in our database, 2 of them funded. They include ViaCyte, Capricor Therapeutics and Neurona Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| viacyte.com | 1999 | San Diego, United States | $389.03M | 126 | Cell therapy for diabetes is developed from stem cells. | |
| capricor.com | 2005 | Los Angeles, United States | 62 | Regenerative medicine for cardiovascular disorders is developed using cell-based platforms. | ||
| neuronatherapeutics.com | 2008 | San Francisco, United States | $417.69M | 67 | Cell-based therapies are developed for intractable neurological diseases. |
Detailed competitors of DiscGenics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of DiscGenics
The website of DiscGenics (discgenics.com) receives about 2.8K visits a month.
- Monthly visits2.8K
▲ 3.5% vs previous month
Websites whose visitors overlap most with DiscGenics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
1post.jp | 1post.jp | 100% | #458,845 | – | |
| iromgroup.co.jp | 63% | 14.2K | #1,401,786 | View details | |
| genomeweb.com | 61% | 116.4K | #371,609 | View details | |
| yakuji.co.jp | 60% | #354,518 | View details |
Top companies in Cell Therapy
3 companies that operate in the same segment as DiscGenics (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Discgenics
Complete news archive for DiscGenics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DiscGenics
DiscGenics was founded in 2008 and raised its 1st funding round 3 years after it was founded.
DiscGenics is headquartered in Salt Lake City, United States. It is registered at Salt Lake City, Utah, United States.
DiscGenics is a funded company, having raised a total of $65.84M across 3 funding rounds to date. The company's 1st funding round was a Seed of $1.84M, raised on Oct 2011.
DiscGenics has 45 employees.
DiscGenics was established in 2008 in Salt Lake City, United States, within the spinal therapeutics sector. A tissue engineering approach is employed, leveraging proprietary adult human disc stem cells to address degenerative disc disease. Two products are under development: Injectable Discogenic Cell Therapy (IDCT), an off-the-shelf allogeneic treatment for moderately degenerated discs delivered via non-surgical percutaneous injection, and Surgical Discogenic Cell Therapy (SDCT), a minimally invasive implant for herniated discs.
DiscGenics's top competitors include Neurona Therapeutics, Capricor Therapeutics and ViaCyte.
DiscGenics has 3 investors. Key investors include CareNet, Mitsubishi UFJ Capital, and Medical Incubator Japan.
DiscGenics operates through Discgenics, Inc..